Sclerostin Inhibitors
1 drugsAbout Sclerostin
Sclerostin, encoded by the *SOST* gene, is a secreted glycoprotein produced by osteocytes. It inhibits the Wnt signaling pathway by binding to LRP5/6 receptors on osteoblasts, suppressing bone formation.
Sclerostin is a therapeutic target for conditions with reduced bone mass. Currently, there is no genetic evidence data available linking sclerostin to specific diseases.
EVENITY (romosozumab) is the only approved drug targeting sclerostin, developed by Amgen for osteoporosis. It is a biologic (other) modality, placing sclerostin-targeted therapies in the 'other' therapeutic area category.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 80% attractiveness score.
- White space opportunity in Bladder Cancer with only 1 trials.
Top Sclerostin Drugs
Amgen is the only company with an approved drug targeting sclerostin.
The market is highly concentrated, indicating potential entry barriers or a first-mover advantage for Amgen.
Sclerostin Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Sclerostin, using biologic (other) modality.
The lack of modality diversity suggests an opportunity to develop small molecule or alternative biologic approaches.
Sclerostin Clinical Trials 36 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 5 | 0 | 1 | 100% |
| Phase 2 | 8 | 5 | 1 | 2 | 83% |
| Phase 3 | 10 | 8 | 0 | 2 | 100% |
| Phase 4 | 11 | 3 | 0 | 8 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Sclerostin Drug Approval Timeline (2019 - 2019)
The first and only drug, EVENITY, was approved in 2019.
The recent approval and lack of subsequent approvals suggest a potentially unsaturated market with room for new entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 34 clinical trials targeting Sclerostin.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities